KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Current Assets (2016 - 2025)

Historic Current Assets for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $28.5 billion.

  • AbbVie's Current Assets rose 271.37% to $28.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 billion, marking a year-over-year increase of 271.37%. This contributed to the annual value of $25.6 billion for FY2024, which is 2248.35% down from last year.
  • According to the latest figures from Q3 2025, AbbVie's Current Assets is $28.5 billion, which was up 271.37% from $29.3 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Current Assets registered a high of $38.9 billion during Q1 2024, and its lowest value of $25.6 billion during Q4 2024.
  • Moreover, its 5-year median value for Current Assets was $28.5 billion (2025), whereas its average is $29.3 billion.
  • As far as peak fluctuations go, AbbVie's Current Assets tumbled by 4866.69% in 2021, and later surged by 4674.95% in 2024.
  • AbbVie's Current Assets (Quarter) stood at $27.9 billion in 2021, then increased by 1.92% to $28.5 billion in 2022, then increased by 15.95% to $33.0 billion in 2023, then decreased by 22.48% to $25.6 billion in 2024, then increased by 11.56% to $28.5 billion in 2025.
  • Its Current Assets stands at $28.5 billion for Q3 2025, versus $29.3 billion for Q2 2025 and $27.7 billion for Q1 2025.